Mather Group’s Apyx Medical APYX Stock Holding History

Mather Group’s Portfolio APYX Stock Details APYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,000	Closed	-$5.03K	–	536
2023 Q2	$5.03K	Buy	+1,000	New	+$5.07K	﹤0.01%	603

Other funds holding APYX

Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return

Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Mather Group's APYX Position: Q3 2023 in Review

Mather Group sold out of Apyx Medical (APYX) in Q3 2023, closing a stake of 1,000 shares — an estimated $5.03K sold.

Mather Group first reported a position in APYX in Q2 2023 and held it in 1 quarter. The position peaked at $5.03K in Q2 2023. 62 funds tracked by Wall St. Rank hold APYX as of Q3 2023.

Mather Group reported no remaining Apyx Medical position as of Q3 2023 after selling out during the quarter.
Mather Group sold 1,000 Apyx Medical shares in Q3 2023, an estimated $5.03K.
Mather Group first reported a position in Apyx Medical in Q2 2023 and held it in 1 quarter.
Mather Group's Apyx Medical position peaked at $5.03K in Q2 2023.
62 funds tracked by Wall St. Rank held Apyx Medical as of Q3 2023.

Based on Mather Group's 13F filing for Q3 2023, filed 13 Nov 2023.